mProX™ Human P2RY4 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Almost all human tissues express members of the G protein-coupled P2Y receptor family, which is highly sought after as a possible treatment target for a wide range of illnesses, particularly cardiovascular and neurodegenerative disorders. Uridine 5'-triphosphate (UTP) and adenosine triphosphate (ATP) act as mediators for P2RY4 activation. P2RY4 is highly expressed throughout the body, including the heart, digestive system, skin, and central nervous system. P2RY4 is thought to control chloride secretion in the digestive system. As a result, P2RY4 antagonists are potential targets for the therapy of diarrhea, while P2RY4 agonists may be utilized to treat cystic fibrosis. Additionally, it has been suggested that P2RY4 controls how the brain produces the amyloid precursor protein (APP). P2RY4 antagonists are potential therapeutic drugs for the treatment of Alzheimer's disease since the buildup of APP in the brain is linked to the development of the condition. Although there haven't been any reports of prospective P2RY4 antagonists to date, this is a promising area for the creation of selective P2RY4 antagonists. The customized P2RY4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.